Women post-menopause with ‘strong family history’ of breast cancer encouraged speak to GP about drug, expert says ...

Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole, indicating that the drug may be an ...

The mean C max for anastrozole after a single 1mg dose was 17.8 and 18.6 µg/L in Japanese and Caucasians, respectively. AUC was 1040 µg/L h in Japanese and 930 µg/L h in Caucasians.

Patients (N = 114) were randomly assigned to either bicalutamide (150 mg/d) plus placebo or in combination with tamoxifen (20 mg/d) or anastrozole (1 mg/d) for 48 weeks. Gynecomastia, breast pain, ...

BMI was observed to be associated with suppressed levels of plasma estradiol and estrone sulfate in postmenopausal women with early ER-positive breast cancer who were treated with the aromatase ...

PATIENTS AND METHODS: Twelve postmenopausal women with estrogen receptor–positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2.5 mg PO once daily, each ...

Twenty-six patients were randomly allocated to treatment with anastrozole 1 mg (n=13) or 10 mg (n=13), once daily. Before and after 12 weeks' treatment, patients were infused with 3H-Δ4 ...

In the efficacy study, the patients with advanced breast cancer received anastrozole 0.5 or 1 mg/day for 12 weeks or more and tumour response was determined at 4-week intervals during treatment.